Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
STAMFORD, Conn., March 08, 2016 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the fourth quarter and full year ended December 31, 2015 on March 15, 2016 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
[email protected]
